Rakotomanomana, F
Drug-Disease Interactions: No interactions found/established
Patients who have an ischemic stroke in the morning, or onset of their active period, are not only at a greater risk for poor outcome based on the hyperfibrinolytic morning state, but additionally, response to thrombolytic intervention is less efficacious during the morning time points
800-69-MERIT / 800-696-3748 SKU 029464516687 NDC 70069-0005-10 Manufacturer Number 70069000510 Login to see prices & order NDC Number 70069-0005-10 / 70069000510 Manufacturer: Somerset Therapeutics, LLC Application B12 Deficiencies Strength: 1,000mcg/mL Multiple Dose Vial Storage Requirements USP Controlled Room Temperature Type Intramuscular or Subcutaneous Volume 30 mL Related products DEPO-MEDROL 80MG/ML, 5ML, (METHYLPREDNISOLONE ACETATE INJ SUSPENSION, USP), MDV, NDC 00009030602 NON-RETURNABLE Login to see prices & order KENALOG-10 (TRIAMCINOLONE ACETONIDE INJ SUSPENSION, USP) MDV, 10MG/ML, 5ML Login to see prices & order KENALOG-40 (TRIAMCINOLONE ACETONIDE INJ SUSPENSION, USP), MDV 40MG/ML, 10ML Login to see prices & order FOLIC ACID INJECTION, USP, MDV, 5MG/ML, 10ML NDC 6332318410 Login to see prices & order Call 800 69 MERIT for pharmaceuticals, medical devices and related professional healthcare products
BENEFITS/ CLINICAL TRIALS The research interest in IGF-1 LR3 is primarily focused on its enhanced anabolic (tissue-building) and lipolytic (fat-burning) potency compared to the native hormone
